Return to Search

Administration intraveineuse de sécrétine dans le traitement des troubles du spectre autistique (TSA)

Intravenous Secretin for Autism Spectrum Disorders (ASD)

By Williams, Katrina; Wray, John A.; Wheeler, Danielle M.

Summary

This online article, written in French, summarizes a research review conducted to determine whether intravenous infusion of secretin, a gastrointestinal hormone, is an effective treatment for autism. Findings consistently indicated that secretin was not associated with reductions in autism symptoms. The authors therefore suggest that secretin should not be recommended or administered as an autism treatment.

This resource is available in English, Croatian, French, and Spanish.

Cochrane is a “global independent network of researchers, professionals, patients, carers, and people interested in health.” [Website] The network reviews evidence about health treatments.

For full text or more information

Visit www.cochrane.org/fr/CD003495/administration-intraveineuse-de-secretine-dans-le-traitement-des-troubles-du-spectre-autistique-tsa

Subject(s)

This online article is in French

Publication:

Cochrane
2012

Is there a mistake in this record?
Please email us at info@actcommunity.ca

ACT provides the resources gathered in the Autism Information Database as a service. We cannot guarantee the suitability or effectiveness of any of the resources listed. We caution all users to be critical consumers; see MedlinePlus Guide to Healthy Web Surfing. ACT reserves the right to remove or refuse a listing, at our discretion.